Skip to main content
S&P 5007,666.45+0.19%DOW50,926.56+0.04%NASDAQ26,871.60+0.04%BTC$84,755.00+1.55%ETH$2,706.86+0.88%GOLD$4,188.70-0.32%OIL$93.13+0.28%
Smart Investors Daily
SID Premium
KA

AMEX · KAPA

Kairos Pharma, Ltd.

Healthcare · Biotechnology

$1.56

Down-$0.08 (-4.88%)

Updated Oct 2, 2026, 5:03 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
16.86M
P/E ratio
-3.24
Dividend yield
0.00%
52-week range
$0.22 – $1.91
Volume
79.13K
Avg. volume
529.54K

Price performance · KAPA

KAPA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 1, 2026

KAPA closed at $1.56 after 20 trading sessions, down 6.59% for the selected period.

Last close
$1.56
Period change
-6.59%
Period low
$1.56
Period high
$1.85
Daily close
View OHLC price history
KAPA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 1, 2026$1.59$1.65$1.47$1.5679.13K
Sep 30, 2026$1.71$1.78$1.60$1.6499.47K
Sep 29, 2026$1.68$1.7552$1.64$1.6653.28K
Sep 28, 2026$1.74$1.798$1.6503$1.6853.5K
Sep 25, 2026$1.77$1.7799$1.72$1.7242.32K
Sep 24, 2026$1.70$1.82$1.695$1.77300.91K
Sep 23, 2026$1.75$1.7775$1.70$1.7363.38K
Sep 22, 2026$1.78$1.81$1.70$1.78247.93K
Sep 21, 2026$1.75$1.80$1.70$1.79126.88K
Sep 18, 2026$1.81$1.84$1.72$1.73168.74K
Sep 17, 2026$1.84$1.84$1.78$1.8133.86K
Sep 16, 2026$1.84$1.84$1.81$1.815.53K
Sep 15, 2026$1.79$1.89$1.76$1.8538.05K
Sep 14, 2026$1.70$1.86$1.70$1.8453.54K
Sep 11, 2026$1.6866$1.765$1.67$1.75833.2K
Sep 10, 2026$1.69$1.73$1.6206$1.6832.6K
Sep 9, 2026$1.76$1.80$1.66$1.6681.9K
Sep 8, 2026$1.85$1.89$1.77$1.77174.36K
Sep 4, 2026$1.67$1.91$1.66$1.84306.73K
Sep 3, 2026$1.55$1.6899$1.55$1.6747.9K

Latest KAPA news

The latest Smart Investors Daily articles mentioning KAPA.

Stock researchCompany · Overview

KAPA research

Overview

Company profile and research snapshot.

Company profile

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
KAPA recent ratings
DateFirmRatingTarget
Nov 19, 2025D. Boral CapitalBuy—
Nov 4, 2025D. Boral CapitalBuy—
Oct 20, 2025D. Boral CapitalBuy—
Oct 7, 2025D. Boral CapitalBuy—
Sep 19, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 23, 2026

Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA

LOS ANGELES, September 23, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the 24th Annual Discovery on Target Drug Discovery Conference. The conference is being held on Sept. 28 to Oct. 1 at the Sheraton Boston Hotel with sessions available on demand on the conference’s website.

Yahoo · Sep 9, 2026

Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

LOS ANGELES, September 09, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By